2022-01-22
2832
分享到：
阿尔茨海默氏症(Alzheimer’s)研究抗体在帮助科学家找到治疗阿尔茨海默氏症和其他痴呆症的方面发挥了重要作用。根据阿尔茨海默氏症协会(Alzheimer’s Association)的数据，全球有4700万人和530万美国人受到这种疾病的影响，预计到2050年，这一数字将增加两倍。随着婴儿潮一代的老龄化，预计将有2800万人患上这种疾病，成本将上升到美国所有医疗保险支出的近四分之一。
自1906年阿洛伊修斯·阿尔茨海默(Aloysius Alzheimer)博士首次描述这种疾病以来，科学家们在了解这种疾病如何影响大脑方面取得了显著进展。十多年后，在理解和治疗方面的突破为阿尔茨海默氏症患者带来了希望。
这些ImmunoStar抗体已在阿尔茨海默氏症研究中得到证实。现在已经有数百篇引用这些抗体的出版物。ImmunoStar的抗体稳定、高滴度，且批次间保持一致，以确保成功染色并具有出色的价值。
___________________________________________________________________________________________________________________________________________ | |
| |
___________________________________________________________________________________________________________________________________________ | |
| |
___________________________________________________________________________________________________________________________________________ | |
| |
___________________________________________________________________________________________________________________________________________ | |
| |
___________________________________________________________________________________________________________________________________________ | |
The antiserum demonstrates strongly positive labeling of rat raphe nuclei, hypothalamus, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. | |
___________________________________________________________________________________________________________________________________________ | |
The ImmunoStar antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat median eminence using indirect immunofluorescent and biotin/avidin-HRP techniques. | |
___________________________________________________________________________________________________________________________________________ | |
The antibody has a proven strong biotin-streptavidin/HRP staining at 1/1,000-1/1,200 dilution in rat globus pallidus and amygdala. | |
阿尔茨海默病和相关疾病的诊断和治疗的最新消息、发现和发展。 | |
400-888-0207
The ImmunoStar monoclonal Tyrosine Hydroxylase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat catecholamine neuron systems using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilution is 1/4000 – 1/8000 with the biotin/avidin-HRP technique. This antibody has been used successfully for IHC, ICC, FC, and IP.
The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, raphe nuclei and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques.
The antibody has a proven strong Biotin-Streptavidin/HRP staining at a 1/4000-1/6000 dilution in rat amygdala, cortex, and suprachiasmatic nucleus.
